FLKS Insider Trading Activity and SEC Form 4 Filings
FLKS insider trading summary
No open-market insider purchases or sales of Flex Pharma, Inc. (FLKS) have been reported on SEC Form 4 in the past 12 months.
Latest FLKS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 9, 2019 | Boston Foundation, Inc. | 10% Owner | Sell | $124K (337,000 @ $0.37) |
| Jan 8, 2019 | Boston Foundation, Inc. | 10% Owner | Sell | $104K (263,000 @ $0.40) |
| Oct 16, 2018 | Christoph H Westphal | 10% Owner | Sell | $2.9M (3,212,861 @ $0.92) |
| Oct 16, 2018 | Longwood Fund II, L.P. | 10% Owner | Sell | $2.9M (3,212,861 @ $0.92) |
| Nov 8, 2016 | Christoph H Westphal | President and CEO | Buy | $51K (7,000 @ $7.31) |
| Nov 7, 2016 | Christoph H Westphal | President and CEO | Buy | $51K (8,870 @ $5.70) |
| Nov 7, 2016 | John P. McCabe | VP of Finance & Treasurer | Buy | $10K (1,650 @ $6.01) |
| Jun 23, 2016 | Christoph H Westphal | President and CEO | Buy | $30K (2,700 @ $11.28) |
| Jun 22, 2016 | Christoph H Westphal | President and CEO | Buy | $32K (2,900 @ $11.03) |
| Jun 21, 2016 | Christoph H Westphal | President and CEO | Buy | $31K (2,800 @ $11.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.